Skip to Content

Verquvo FDA Approval History

FDA Approved: Yes (First approved January 19, 2021)
Brand name: Verquvo
Generic name: vericiguat
Dosage form: Tablets
Company: Merck
Treatment for: Heart Failure with Reduced Ejection Fraction (HFrEF)

Verquvo (vericiguat) is a soluble guanylate cyclase (sGC) stimulator indicated to reduce the risk of cardiovascular death and heart failure (HF) hospitalization following a hospitalization for heart failure or need for outpatient IV diuretics, in adults with symptomatic chronic HF and ejection fraction less than 45%.